NCT03386942

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	Farletuzumab Ecteribulin	Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.

Timeline

• Start date: 2017-11-28
• Primary completion: 2022-10-26
• Completion: 2022-10-26
• First posted: 2017-12-29
• Last updated: 2022-11-28

Locations

10 sites across 1 country: Japan